Gedea Biotech
Antibiotic-free treatment for bacterial vaginosis
Gedea Biotech has developed the vaginal tablet pHyph, a treatment for bacterial vaginosis (BV) that is both effective against BV and strengthens the vaginal microbiome to increase resilience against recurrent infections.
Behind the idea are several years of basic research where a cross-disciplinary research group identified a substance that lowers pH and promotes the growth of lactobacilli, which are necessary for a healthy microbiome. The substance has also shown promising results against vaginal candida infection (vaginal yeast infection).
pHyph is antibiotic-free, safe, and effective, and provides an important alternative in the treatment of vaginal infections. In 2025, pHyph received CE marking according to EU MDR and was thereby ready for launch in Europe.
Gedea Biotech
Antibiotic-free treatment for bacterial vaginosis.
Founded by Helena Strevens, Olov Sterner, Ulf Ellervik and Sophie Manner.
Portfolio company since 2016.
Portfolio Manager LU Ventures:
christine [dot] widstrand [at] innovation [dot] lu [dot] se (Christine Widstrand), phone +46 70 928 63 78